US minority veterans face unequal access to Ozempic and Wegovy, study finds

By Nancy Lapid

(Reuters) - U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk (NYSE:NVO )'s highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday (NASDAQ:MNDY ), the U.S. Veterans Day holiday.

In the U.S. Veterans Affairs Medical (TASE:PMCN ) System, Black patients and those of Asian or Native American ancestry were less likely to receive semaglutide than white patients for diabetes or weight loss, study leader Dr. Rebecca Tisdale of the VA Palo Alto Health Care System in Menlo Park, California, said.

Semaglutide is sold by Novo Nordisk as Ozempic for treatment of type 2 diabetes and as Wegovy for weight management. It belongs to a class of drugs known as GLP-1 receptor agonists.

Researchers reviewed data on 1.9 million patients who are overweight or considered obese, including nearly 809,000 with diabetes, at U.S. VA facilities, where access to insurance is not a barrier to care.

The odds of receiving a semaglutide prescription were 26% lower for Black patients with diabetes and 9% lower for Black patients without diabetes than for white patients in those two groups, they found.

There were no significant differences between Hispanic and white veterans. But for veterans identified as American Indian/Alaskan Native and Asian/Native Hawaiian/Pacific Islander, those with diabetes had 17% lower odds of receiving a semaglutide prescription compared to white patients.

“Across all minority race groups, the most significant undertreatment was among those with diabetes,” the researchers said in a report of the study published in Circulation Cardiovascular Quality and Outcomes.

“This concerning pattern may reflect disparities within disparities," they said, noting that some racial and ethnic groups are less likely to receive these novel therapies in general, and "the most severe undertreatment is among those with more than one indication and thus most to gain.”



“The VA’s policies around allocating GLP-1 receptor agonists like semaglutide are still very much evolving as the supply of these drugs from the manufacturer and demand from patients and doctors continues to change,” said Tisdale, who will present the findings at the upcoming American Heart Association scientific meeting in Chicago.

“Our hope is that studies like ours ensure that equity is explicitly considered as these regulations are formed, she said.”

Source: Investing.com

Последние публикации
Futures dip as focus shifts to inflation data for clues on Fed's rate path
13.11.2024 - 15:00
Nokia buys world's largest API hub from Rapid to cash in on 5G
13.11.2024 - 15:00
Guardian quits X social media platform, citing racism and conspiracy theories
13.11.2024 - 15:00
Plug Power offers softer-than-expected 2025 sales guidance, appoints new president
13.11.2024 - 15:00
Redburn Atlantic downgrades rating of Starbucks to "Sell"
13.11.2024 - 15:00
This retailer is Telsey's Top Pick for the upcoming holiday season
13.11.2024 - 15:00
UK finance firms seek 'bold' reforms to counter Wall St ascendancy
13.11.2024 - 15:00
Offshore wind cable maker Nexans says it might turn US plant into export hub
13.11.2024 - 15:00
Mastercard offers mid-term guidance, shares rise
13.11.2024 - 15:00
Just Eat Takeaway offloads US unit Grubhub for $650 million, shares jump
13.11.2024 - 15:00
US stock futures bounce higher after in line CPI release
13.11.2024 - 15:00
UK markets watchdog softens 'overcooked' naming and shaming plan
13.11.2024 - 15:00
These are the top 5 tech stocks to own in 2025: Evercore
13.11.2024 - 15:00
Riskified hikes annual revenue guidance, reports Q3 profit
13.11.2024 - 15:00
Super Micro Computer stock falls after delaying 10-Q filling
13.11.2024 - 14:00

© Analytic DC. All Rights Reserved.

new
Анализ рынка Как повлият завтра отчет NFP на курс доллара США?